Prolia (denosumab) Important Safety Information from Amgen Ireland Limited as approved by the Irish Medicines Board

Notice type: 3rd Party Publications

Date: 21/02/2013

 

Problem Or Issue:
Important Safety Information communication from Amgen Ireland Limited on the risk of atypical femoral fracture associated with the use of denosumab.

Important Safety Information - Prolia (denosumab)


« Back